Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is ...

One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...